Leaving Teva













I enjoyed my time there. I know I am in the minority but Kare destroyed this place in minutes.
Teva was for all essential purposes bankrupt when Kare came on board to help keep it afloat. Sure he did some really harsh things with the layoffs and shuttering plants but what other option did he have there'd be no Teva today without the things he did.
 






I enjoyed my time there. I know I am in the minority but Kare destroyed this place in minutes.
Kare did what had to be done after years and years of appalling mismanagement and graft by the Tel Aviv mafia who single-handedly destroyed the company with a series of reckless and ego-driven actions, spending up large on the Copaxone war chest while acting as a repository for countless grifters in Israel and around the world.
 






I enjoyed my time there. I know I am in the minority but Kare destroyed this place in minutes.
I disagree Kare did what had to be done to save a company that was on life support due to years of incompetence. At least he wasn't as overt as the current CEO who seems to be putting his friends and previous colleagues into executive positions throughout Teva.

I used to work at Teva Canada and prior to that Novopharm, it was a great place to work and even when Teva bought us we were managed out of the USA they just let us get on with business. I got out when Teva global got more and more involved in the business, the guy who runs the International Markets group is a nice guy but really has no idea what he's doing and seems to hire yes men and flim-flam merchants.

Talking to the people who are still in the business they say it's a pretty awful place to be working and becoming more and more like a cult where anyone who doesn't worship at the altar of Teva is moved on. By all acounts this is the same in South America and Asia Pacific where buffoons are running the business in those regions.

It will be interesting to see what happens in the next few years - if the single R&D does well in Phase 3 I expect a decoupling of generics (or what's left of it) and the R&D business will follow pretty quickly.